Ledipasvir and sofosbuvir

  • Part D specialty tier in 77% of formularies (2026Q3)

Therapy management checklist

Screening, baseline and ongoing monitoring with the label's stated frequency, hold and discontinue criteria, and counseling points, each quoted from the FDA label.

Loading the therapy management checklist…

Storage and cold chain

Ledipasvir and sofosbuvir: storage and handling

Freezing
Not addressed
Room temperature
at or below 30°C (86°F)
Label statement
Store at room temperature below 30 °C (86 °F).
Room temperature
at or below 30°C (86°F)
Label statement
Store ledipasvir and sofosbuvir tablets at room temperature below 86°F (30°C).
Back into the refrigerator
Not addressed
Light
Not addressed
Shaking
Not addressed

Temperature excursion helper

Answers only from this label's storage statements. It does not judge whether a product is still usable beyond what the label states.

Within the label's stated room-temperature allowance (at up to 30°C (86°F)). Follow the label's instructions for what to do next.

Entered: 1 day at up to 77°F (25°C).

Store at room temperature below 30 °C (86 °F).

If anything else happened to the product, or you are unsure, Contact the manufacturer at 1-800-445-3235 (the number printed on the label) about this product.

Where the label prints this number
Manufactured for: Asegua Therapeutics LLC, an affiliate of Gilead Sciences, Inc., Foster City, CA 94404 For more information, call 1-800-445-3235 or go to www.asegua.com.
All storage statements on the label (2)
  • Store at room temperature below 30 °C (86 °F).
  • Store ledipasvir and sofosbuvir tablets at room temperature below 86°F (30°C).

FDA label version 8, effective January 10, 2025. DailyMed

Dosing and titration calendar

Built only from the schedules the label states (loading, titration, day schedules, cycles and weight bands). Steps the label states in words the calendar cannot place are shown, not guessed.

Loading dosing schedules…

Medicare Part D coverage

28%of plans list it
100%of those: prior authorization
0%step therapy
82%quantity limit
97%specialty tier

5,496 Part D plans, CMS formulary files 2026Q3. Look up tier, PA, step therapy and quantity limits by plan

Patient assistance

No manufacturer program page is listed for this drug yet.

Independent foundations and the full directory (checked 2026-11-06). Eligibility and amounts are set by each program; open its page for them.

For licensed clinicians. Use with clinical judgment. Statements are quoted from the FDA label; confirm against the label for the product you are using.